Almonty's Sangdong Milestone Gives GBC Ammunition for a 44% Price Target Lift

GBC AG lifts Almonty's target to $30 on Sangdong's commercial production; $300M buyback signals confidence amid 21% stock slide.

The tungsten producer's transition from mine developer to commercial operator has prompted GBC AG to raise its price target on Almonty to $30 from $20.89, while the company simultaneously gears up for a $300 million share repurchase program. The two developments, announced within days of each other, underscore a management team convinced the market has yet to price in the value of its South Korean flagship asset.

GBC's revised target, delivered Tuesday, rests primarily on Sangdong's shift into commercial production — a step change that analysts say transforms the project from a long-promised value driver into an actual cash generator. The processing facility in Gangwon Province began handling ore stockpiles last week, producing saleable tungsten concentrate, with throughput operations having started mid-month.

Buyback Backs the Bull Case

The board's decision to authorize a buyback of up to 14.4 million common shares — worth as much as $300 million over 36 months — was framed by management as a direct response to the gap between the current share price and the underlying value of the company's tungsten assets. The program is slated to begin Monday, August 24, 2026, and arrives at a moment when the stock has shed roughly 21.4 percent since mid-June, a slide that GBC believes has left the valuation out of step with operational progress.

That disconnect is partly explained by the mechanics of the company's recent financing. Almonty closed an oversubscribed $800 million convertible bond offering in June, using the proceeds to retire its KfW loan in full just over a month ago. The equity overhang from that instrument, combined with the typical volatility of a mine ramp-up, has weighed on the shares even as the operational picture brightens.

A Tale of Two Earnings Pictures

The financials tell a story of dramatic top-line growth tempered by accounting noise. Second-quarter revenue came in at C$43.0 million, up 498 percent year over year, while the company reported net income of C$181.8 million. But embedded in that profit figure were non-cash derivative valuation gains totaling C$173.1 million — a distortion that flatters underlying operating performance.

The secondary listing's numbers, reported in US dollars, show revenue of $43 million for the three months ended June 30, 2026, with adjusted EBITDA of $17.6 million and diluted earnings per share of $0.64.

Not everyone is convinced the near-term trajectory is as smooth as management suggests. Diamond Equity trimmed its fiscal 2026 earnings estimate to $0.39 per share from $0.55 on August 19, citing concerns about short-term earnings growth, though it maintained its buy recommendation. The revision — which came days after the production and delisting announcements — highlights the uneven nature of mine ramp-ups, where operational milestones and financial results often move at different speeds.

Contracts, Indexes, and a Streamlined Listing

The commercial picture extends beyond Sangdong's startup. In July, Almonty extended its offtake agreement with Global Tungsten & Powders to a 21-year term, increased contracted volumes by 40 percent, and improved pricing terms by 6.3 percent. June brought inclusion in the Russell 1000 and Russell 3000 indexes, bolstering the company's institutional visibility beyond the mining niche.

The corporate restructuring continues on the listing front. Almonty has already executed a voluntary delisting from the Toronto Stock Exchange effective July 31, 2026, with its ASX CDI quotation expected to be suspended at the close of trading on August 28 and a final delisting set for September 1. That leaves Nasdaq (ALM) and Frankfurt (ALI1) as the remaining venues, a consolidation that should concentrate trading liquidity.

For GBC, the combination of commercial production, a strengthened balance sheet, and secured long-term offtake volumes justifies the higher target — even as the near-term earnings debate between optimists and skeptics continues to play out in the share price.